SB 1868 would expand Texas law governing kratom products and controlled substances. It redesignates the existing kratom chapter, tightens product testing and labeling requirements, and makes it a criminal offense to sell kratom products that are not properly tested or labeled. The bill requires testing by an in-state ISO/IEC 17025-accredited laboratory for alkaloid content and for contaminants such as heavy metals, pesticides, microbial contamination, and other substances set by rule. It also requires kratom products to include safe-use directions and recommended serving sizes.
The bill adds several new prohibitions on kratom products. It would bar adulterated or contaminated kratom products, products with synthetic or artificial alkaloids, products with higher-than-allowed levels of 7-hydroxymitragynine, prepackaged beverages, and most prepackaged foods containing kratom. It also creates offenses for selling kratom to people under 21, selling kratom within 1,000 feet of a school, falsifying laboratory reports, selling kratom at locations that also sell hemp, tobacco, or alcohol products, and manufacturing or selling kratom for smoking or in pill/tablet form. Civil penalties are increased substantially, and the attorney general or local prosecutors may bring enforcement actions.
In addition to regulating kratom products, SB 1868 amends the Texas Controlled Substances Act to add kratom alkaloids and related synthetic or artificial equivalents to Penalty Group 1, along with tianeptine-related language, while also updating controlled-substance definitions. The bill also makes a broad set of technical and substantive changes to Penalty Groups 1 and 2, including numerous synthetic opioids, stimulants, hallucinogens, and cannabinoid-related substances. These changes would affect manufacturers, processors, retailers, laboratories, prosecutors, and consumers of kratom and related products.
The general sentiment reflected in the bill’s progress appears to be supportive of stronger regulation and enforcement, as shown by the Senate’s 26-4 votes on suspension of rules, third reading, and journal entry. That said, the bill’s scope suggests a significant public-health and law-enforcement approach to kratom rather than a permissive consumer-product framework. The absence of committee transcript discussion limits insight into detailed arguments, but the vote margin indicates substantial support with some opposition.
The main points of contention are likely the bill’s broad criminalization of kratom sales and its treatment of kratom alkaloids as controlled substances, which could be viewed as overly restrictive by kratom users, retailers, and industry advocates. Other potentially disputed provisions include the age limit of 21, the school-zone restriction, the ban on sales at locations that also sell hemp, tobacco, or alcohol, and the prohibition on pills, tablets, and smoking products. Supporters would likely emphasize product safety, contamination prevention, and youth access restrictions, while opponents may argue the bill goes beyond safety regulation and effectively suppresses lawful kratom commerce.
The bill would amend the Health and Safety Code by creating a more detailed regulatory and enforcement scheme for kratom products and by expanding the Texas Controlled Substances Act to include kratom alkaloids and related synthetic or artificial equivalents in Penalty Group 1. It increases civil penalties for chapter violations, creates several new Class A misdemeanor offenses and one third-degree felony for false laboratory reports, and authorizes state and local prosecutors to enforce the civil penalty provisions. It also affects Chapter 431 food/adulteration rules and Chapter 481 controlled-substance classifications, thereby changing the legal status of kratom-related substances and the obligations of processors, retailers, laboratories, and consumers.
The available voting history suggests the bill had meaningful support in the Senate, with 26 yeas and 4 nays on multiple procedural and passage votes. That pattern indicates the measure was broadly accepted by the chamber, though not unanimously. Because there are no committee transcript excerpts, the record does not show detailed debate, but the bill’s content points to a generally pro-regulation, public-safety-oriented sentiment among supporters, with some likely concern from members wary of criminal penalties and controlled-substance expansion.
The likely areas of contention are the bill’s strict treatment of kratom as a controlled substance, the criminal penalties attached to product sales and labeling violations, and the breadth of the sales restrictions. Retailers and kratom advocates may object to the age-21 limit, the school-zone ban, the prohibition on selling kratom in stores that also sell hemp, tobacco, or alcohol, and the ban on pills, tablets, and smoking products. Supporters are likely to argue that these provisions are necessary to prevent contamination, deceptive labeling, youth access, and unsafe product forms, while opponents may view them as overbroad and harmful to lawful businesses and adult consumers.